Evidence map›Paper›PMID 29307283›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2018

Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.

Michael D Ludwig, Ian S Zagon, Patricia J McLaughlin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Opioid Signaling in Multiple Sclerosis: Emerging Targets for Repair.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Article
  4. Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.Medical sciences (Basel, Switzerland) · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Michael D LudwigDepartment of Neural and Behavioral Sciences, College of Medicine, Pennsylvania State University, PA 17033, USA.
Ian S ZagonDepartment of Neural and Behavioral Sciences, College of Medicine, Pennsylvania State University, PA 17033, USA.
Patricia J McLaughlinDepartment of Neural and Behavioral Sciences, College of Medicine, Pennsylvania State University, PA 17033, USA.
Pennsylvania State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The endogenous neuropeptide opioid growth factor, chemically termed [Met

Indexed as

AdultAgedAged, 80 and overAnimalsCytokinesEncephalomyelitis, Autoimmune, ExperimentalEnkephalin, MethionineFemaleGlatiramer AcetateHumansImmunosuppressive AgentsMaleMice, Inbred C57BLMiddle AgedMultiple SclerosisNaltrexoneCytokinesEnkephalin, MethionineGlatiramer AcetateImmunosuppressive Agentsmethionine-enkephalin receptorNaltrexoneReceptors, Opioidcytokinesexperimental autoimmune encephalomyelitisIFN-γIL-10IL-6low-dose naltrexoneopioid growth factor

Identifiers

PMID29307283
PMCPMC6022923
OpenAlexW2783722146

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.